# Qiagen partners with NeuMoDx on PCR systems with option to acquire for $234M

Qiagen will commercialize NeuMoDx's PCR-based molecular diagnostic systems outside the U.S. and has an option to acquire all NeuMoDx shares not already owned for approximately $234 million, contingent on milestones.

- Type: Partnership
- Announced: 2018-09-17
- Value: $234.0M
- Status: announced
- Products: NeuMoDx 288 PCR system, NeuMoDx 96 PCR system
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Qiagen](https://endata.com/companies/34370.md)
- [NeuMoDx Molecular](https://endata.com/companies/34371.md) (partner)

## Sources

- [insideprecisionmedicine.com](https://www.insideprecisionmedicine.com/news-and-features/qiagen-partners-with-neumodx-on-pcr-based-mdx-systems-future-merger/), 2018-09-17: "The partnership allows Qiagen to acquire all NeuMoDx shares not currently owned by Qiagen at a predetermined price of approximately $234 million."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.